Authors
Latest:
AstraZeneca's Principles for Product-Related Online CommunicationsIndustry anticipates meaningful guidance from FDA on use of social media
Latest:
Getting Value From End-of-Life-Cycle PharmaceuticalsA review of 84 branded pharmaceutical products with changed ownership as of 2005 shows that many of them can continue to sell, often with much higher prices By Albert I. Wertheimer, PhD, MBA, Temple University, and Ellen F. Loh, BS, MBA, University of Maryland, Baltimore
Latest:
A growing preference for ready-to-administer vaccines: new guidelines, evidence, and trendsVaccine administration is shifting from multidose vials to prefilled syringes for a host of important safety and economic considerations
Latest:
Managing third-party risks in the life sciences industryInternal compliance reviews are not enough; life sciences companies need to assess their third-party business partners
Latest:
A Big Data approach to patient engagement and adherenceCombining high-quality patient-support services with comprehensive and continually updated analytics results in better outcomes
Latest:
Container selection and testing for safe drug product deliveryElaborate testing is necessary to ensure the stability and functionality of today's drug-delivery systems
Latest:
Ten integrated imperatives for pharma commercial transformationThe pharma industry needs to go farther in adapting to new marketplace realities
Latest:
A new way to look at the performance of passive cold-chain shipping containersA 'performance curve' chart for containers could simplify the design process
Latest:
Packaging, serialization and medication adherence: the coming connectionModernized packaging technologies can change the drug-distribution dynamic - and improve overall healthcare
Latest:
Data systems critical to Covid-19 vaccineWith a number of vaccine trials progressing globally, recent data loss and quality control errors have raised the importance of ensuring effective data systems in this effort
Latest:
Emphasize patient interaction in patient support programsHubs and other patient services need to stress the personal
Latest:
Understanding the companion-diagnostics environmentWhile the pharma industry is growing more dependent on companion diagnostics, test developers face an uncertain business model
Latest:
Modified release formulations give new life to drugsBoth pharmacological and economic factors drive the decision to use these technologies
Latest:
Moving up the marketing maturity curveGiven the profound changes in the pharmaceutical commercial model, sales and marketing must deliver integrated customer experiences across channels and adapt through real-time insights
Latest:
The Interoperability IllusionYour serialization systems aren’t as interoperable as you might think
Latest:
Training Executives for Marketing ComplianceConventional training of sales forces is being complemented by executive-level training for corporate compliance
Latest:
Industry should reinforce cargo security practices with TAPA participationUltimately, supply chain integrity should include both temperature control and security against theft or diversion
Latest:
Forecasting Returns When Patents ExpireOverestimating product reserves as loss of exclusivity (LoE) approaches can be a $75-million mistake
Latest:
The outcomes-based reimbursement environmentA changing role for hubs in collecting critical data, raising adherence
Latest:
In Search of the ‘Bad Guy’Fighting for patient affordability doesn’t necessarily require a scapegoat.
Latest:
The Pharma Industry's Place in a Connected Health WorldNew technologies are creating a powerful link between patients and healthcare providers. This Connected Health World has implications for pharmaceutical business practices
